Apotheken | Arzt | Interaktionen | Medikamente | MiGeL | Services | Spital | Zulassungsi.
Fachinformation zu QUVIVIQ™ FILMTABLETTEN:Idorsia Pharmaceuticals Ltd
Vollst. FachinformationDDDÄnderungen anzeigenDrucken 
Fahrtücht.Unerw.WirkungenÜberdos.Eigensch.Pharm.kinetikPräklin.Sonstige H.Swissmedic-Nr.
PackungenReg.InhaberStand d. Info. 
N05CJ03 - ATC-DDD Version 2016. Source: WHO
N - Nervous System
N05 - Psycholeptics

The group is divided into therapeutic subgroups:
N05A - Antipsychotics
N05B - Anxiolytics
N05C - Hypnotics and sedatives

N05C - Hypnotics and Sedatives

This group comprises preparations with mainly sedative or hypnotic actions.
Melatonin receptor agonists are also classified in this group.
See also:
N05A - Antipsychotics
N05B - Anxiolytics
R06A - Antihistamines for systemic use
Combined preparations are classified at separate 4th levels, N05CB and N05CX.
Regarding classification of combined preparations, see comments under N05B - Anxiolytics.
Combined preparations with barbiturates are mainly classified in A03 (mainly antispasmodic effect) or in N02 (mainly analgesic effect).
Combined preparations with barbiturates which remain in N05C are mainly "neurostabilizers".
The group is subdivided according to chemical structure.

The DDDs are based on use of the drugs as hypnotics.
The DDD for melatonin is based on dose recommendations in EU for the 2 mg depot tablet.

N05CJ03 - 
2024 ©ywesee GmbH
Einstellungen | Hilfe | FAQ | Anmeldung | Kontakt | Home